<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50375">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02021929</url>
  </required_header>
  <id_info>
    <org_study_id>819185</org_study_id>
    <nct_id>NCT02021929</nct_id>
  </id_info>
  <brief_title>Sorafenib for Hepatopulmonary Syndrome</brief_title>
  <acronym>SHPS</acronym>
  <official_title>Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this clinical trial is to determine the safety and effects of the study
      drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will
      evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood
      and the function of the lung vessels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Difference in changes in  alveolar-arterial oxygen gradient between sorafenib and placebo groups</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in intrapulmonary shunting between sorafenib and placebo groups</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in hematopoietic progenitor cells and other biomarker levels between sorafenib and placebo groups</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in hematopoietic progenitor cells and other biomarker levels between sorafenib and placebo groups</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatopulmonary Syndrome</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg (2 capsules) taken by mouth once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules taken by mouth once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HPS:

               1. AaPO2 ≥ 15 mm Hg (≥ 20 mm Hg for age &gt; 64 yrs)

               2. Intrapulmonary shunting

               3. Absence of significant restriction (TLC &lt; 70%) or obstruction (FEV1 &lt; 80% &amp;
                  FEV1/FVC &lt; 70%)

               4. Presence of cirrhosis and/or portal hypertension

          -  Child-Pugh class A or B liver disease

          -  Platelet count ≥ 60 ×10e9 per liter

          -  Hemoglobin ≥ 8.5 g per deciliter

          -  International normalized ratio ≤ 2.3

          -  Albumin ≥ 2.8 g per deciliter

          -  Total bilirubin ≤ 3 mg per deciliter

          -  Alanine aminotransferase and aspartate aminotransferase ≤ 5 times the upper limit of
             the normal range

          -  Serum creatinine ≤ 1.5 times the upper limit of the normal range and not receiving
             dialysis

          -  Negative pregnancy test (for women of childbearing potential) at both screening and
             baseline visits. Post-menopausal women (defined as no menses for one year) and
             surgically sterilized women are not required to undergo a pregnancy test.

          -  Subjects (men and women) of childbearing potential must agree to use medically
             acceptable contraception beginning at the signing of the Informed Consent Form until
             at least 14 days after the last dose of study drug.

          -  Age ≥ 21 years

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Recent chronic heavy alcohol consumption

          -  Enrollment in a clinical trial or concurrent use of another investigational drug or
             device therapy (i.e., outside of study treatment) during, or within 28 days of
             screening visit

          -  Current hepatic encephalopathy

          -  Active infection

          -  Diagnosis of portopulmonary hypertension

          -  WHO Class IV functional status

          -  Congenital long-QT syndrome

          -  Subjects who have used strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,
             phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of
             greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days
             before randomization

          -  Subjects who are currently taking Coumadin®(warfarin)

          -  Active or clinically significant cardiac disease, including:

               1. Active coronary artery disease

               2. Unstable angina (anginal symptoms at rest), new-onset angina within 12 weeks
                  before randomization, or myocardial infarction within 24 weeks before
                  randomization

          -  Liver or other solid organ transplant recipients

          -  Expectation of liver transplant within four months of randomization

          -  Hepatocellular carcinoma

          -  Uncontrolled hypertension (systolic pressure &gt;140 mm Hg or diastolic pressure &gt; 90 mm
             Hg on repeated measurement) despite optimal medical management.

          -  Any hemorrhage/bleeding event of NCI-Common Toxicity Criteria for Adverse Effects
             v4.0 Grade 3 or higher within 4 weeks before randomization

          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture

          -  Women who are pregnant or breast-feeding

          -  Major surgery 28 days prior to randomization

          -  Subjects with any previously untreated or concurrent cancer except cervical cancer
             in-situ, treated basal cell carcinoma, or superficial bladder tumor.  Subjects
             surviving a cancer that was curatively treated and without evidence of disease for
             more than 3 years before randomization are allowed. All cancer treatments
             (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor
             embolization) must be completed at least 3 years prior to study entry (i.e.,
             signature date of the informed consent form).

          -  Inability to comply with the protocol and/or not willing or not available for
             follow-up assessments
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Kawut, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Sharkoski</last_name>
    <phone>215-746-4186</phone>
    <email>sharkosk@exchange.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Stadheim, RN</last_name>
      <phone>507-284-0141</phone>
      <email>stadheim.linda@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Krowka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University-NewYork-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samina Munir</last_name>
      <phone>212-305-3839</phone>
      <email>sm3417@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Sharkoski, 15</last_name>
      <phone>215-746-4186</phone>
      <email>sharkosk@exchange.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Steven M Kawut, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Goldberg, MD, MSCE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacie Ford</last_name>
      <email>Lacie.L.Ford@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael B Fallon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>sorafenib</keyword>
  <keyword>Hepatopulmonary Syndrome</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatopulmonary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
